Lexaria Bioscience Corp. has announced successful results from a preclinical study demonstrating that its DehydraTECH drug delivery technology enhances brain biodistribution of the GLP-1 drug semaglutide compared to conventional formulations. The study, conducted on Sprague Dawley rats, revealed that DehydraTECH-processed semaglutide achieved higher fluorescent signal intensity in brain tissue across all tested doses, with the 5mg DehydraTECH formulation outperforming even the 15mg Rybelsus equivalent composition.
The enhanced brain delivery is particularly significant because GLP-1 drug performance is increasingly understood to depend on brain neurochemistry involvement. Semaglutide regulates body weight through activation of GLP-1 receptors on multiple brain nuclei, affecting neuronal pathways involved in food intake, reward, and energy expenditure. Improved brain biodistribution could potentially lead to better appetite suppression without causing nausea, which remains one of the most common side effects of current GLP-1 therapies.
Detailed examination of specific brain regions showed that all three DehydraTECH doses tested displayed fluorescence above control groups in key areas including the brainstem, paraventricular nucleus of the hypothalamus, and circumventricular organs. These regions are known for direct semaglutide interaction and play crucial roles in energy homeostasis. The findings suggest that Lexaria's technology may enable unique delivery enhancements that support improved pharmacodynamic performance.
John Docherty, Lexaria President and CSO, noted that the company has previously evidenced higher brain levels with other DehydraTECH-processed active ingredients that demonstrated superior safety and efficacy over controls. The current results align with performance benefits observed in related human clinical testing, including studies identified as GLP-1-H24-1 and GLP-1-H24-2.
The study methodology involved fluorescently tagged semaglutide using cyanine 7 fluorophore for visualization, allowing researchers to track distribution patterns through non-invasive whole-body imaging and ex vivo organ analysis. Tissue collection included examination of multiple organs known to express GLP-1 receptors, with detailed fluorescent imaging providing insights into specific tissue localization patterns and concentrations.
These early-stage results could have substantial implications for the pharmaceutical industry's approach to GLP-1 drug development. Enhanced brain delivery through improved oral formulations may address current limitations in treatment efficacy and side effect profiles. The technology's potential to improve safety and performance characteristics of existing and next-generation GLP-1 drugs represents a significant advancement in metabolic disease treatment options.
Lexaria considers these findings highly encouraging for both additional research and potential industry partnerships aimed at developing safer and more effective GLP-1 medications. The study was conducted by an independent animal research facility specializing in pharmacokinetic evaluations, though the company notes that due to the pilot nature of the research, no statistical analyses were performed.
